Intuitive Surgical, a prominent medical technology firm, is preparing to unveil its financial performance for the first fiscal quarter. Market analysts are keenly anticipating these results, having already adjusted their projections for the company's earnings and revenue. This comes after a recent cautionary notice from the U.S. Food and Drug Administration regarding specific products manufactured by the company, influencing stock movements and expert opinions.

The company, headquartered in Sunnyvale, California, is scheduled to disclose its first-quarter earnings report following the market close on Tuesday, April 21. Financial experts are forecasting an earnings per share of $2.11, marking a notable increase from the $1.81 reported in the corresponding period last year. Furthermore, the consensus revenue estimate for Intuitive Surgical stands at $2.62 billion, a rise from $2.25 billion in the previous year, as detailed by Benzinga Pro data.

Adding a layer of complexity to the upcoming earnings announcement, the U.S. Food and Drug Administration issued an early warning on March 18. This alert highlighted a potentially significant safety concern associated with stapling devices produced by Intuitive Surgical. Following this news, the company's stock experienced a slight dip, closing at $465.60 on Monday, a decrease of 0.8%.

In response to these developments, several Wall Street analysts have reassessed their ratings and price targets for Intuitive Surgical. On April 15, 2026, Truist Securities analyst Richard Newitter maintained a Buy rating but adjusted the price target downwards from $650 to $580. Mizuho analyst Anthony Petrone, on April 13, 2026, upheld a Neutral rating while significantly reducing the price target from $575 to $525. Conversely, BTIG analyst Ryan Zimmerman maintained a Buy rating with a price target of $616 on April 10, 2026. Evercore ISI Group's Vijay Kumar maintained an In-Line rating but lowered the price target from $550 to $480 on April 6, 2026. Most notably, Citigroup analyst Joanne Wuensch upgraded the stock from Neutral to Buy on March 11, 2026, setting a new price target of $590. These varied adjustments underscore the dynamic nature of market sentiment and expert analysis in the healthcare technology sector.

Ahead of the first-quarter earnings release, market participants and investors are closely monitoring Intuitive Surgical's performance. The company's ability to navigate regulatory challenges and meet financial expectations will be crucial in shaping its trajectory in the competitive medical device industry. The revised forecasts from leading analysts provide a snapshot of current market sentiment, reflecting both cautious optimism and specific concerns, particularly in light of the FDA's recent warning.